Fennec Pharmaceuticals Inc. (FENC) Stock Price & Analysis
Fennec Pharmaceuticals Inc. (FENC) fell 1.58% to USD 9.99 as of July 25, 2026 at 06:10 UTC, according to Nexqual real-time market data.
FENC last closed at USD 10.15; the session ranged USD 9.95–10.75 on volume of 84,492 shares. Market capitalization is $347.02M, with a 52-week range of USD 5.65–11.31 (NCM). Source: Nexqual, July 25, 2026 at 06:10 UTC.
Key Statistics (as of July 25, 2026 at 06:10 UTC)
| Price | USD 9.99 |
|---|---|
| Change | ▼ 1.58% (down) |
| Previous Close | USD 10.15 |
| Open | USD 10.25 |
| Day Range | USD 9.95 – 10.75 |
| 52-Week Range | USD 5.65 – 11.31 |
| Volume | 84,492 shares |
| Market Cap | $347.02M |
| Exchange | NCM |
Technical Analysis (FENC)
Nexqual's technical model rates FENC "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 06:10 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.29 (neutral) |
| vs SMA50 | Above (USD 9.86) |
| MACD | 0.14 (positive) |
Analyst Ratings (FENC)
Wall Street analysts rate FENC "None" based on 6 analysts, with a mean price target of USD 15.67 (range USD 13–18), per Nexqual as of July 25, 2026 at 06:10 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15.67 |
| High Target | USD 18 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (FENC)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD 0.02 |
| Revenue Estimate | $16.12M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.01 vs est -0.02 ▲ beat |
| 2025-12-31 | USD -0.1 vs est 0.04 ▼ miss |
| 2025-09-30 | USD -0.02 vs est -0.03 ▲ beat |
| 2025-06-30 | USD -0.11 vs est -0.03 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financials & Fundamentals (FENC)
| Total Revenue | $51.00M |
|---|---|
| Revenue Growth (YoY) | +72.60% |
| Gross Margin | +92.23% |
| Operating Margin | -0.79% |
| Profit Margin | -16.42% |
| ROE | -52.68% |
| Current Ratio | 6.98 |
| Total Cash | $40.18M |
| Total Debt | $0 |
| Free Cash Flow | $-2.37M |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Financial Health Score (FENC)
Nexqual rates Fennec Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:10 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $40M cash, no debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -53%, ROA -5.9% |
Ownership (FENC)
| Insider Ownership | +14.46% |
|---|---|
| Institutional Ownership | +54.32% |
| Shares Outstanding | 34.74M |
| Float | 16.83M |
| Short % of Float | +2.03% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
Leadership (FENC)
Fennec Pharmaceuticals Inc. is led by Jeffrey S. Hackman (age 62), CEO & Director, per Nexqual as of July 25, 2026 at 06:10 UTC.
| CEO & Director | Jeffrey S. Hackman (age 62) |
|---|---|
| Chief Financial Officer | Robert C. Andrade (age 50) |
| Chief Strategy Officer | Christiana Cioffi |
| President of Pharstat Inc | Lei Fang |
Major Backers & Investors (FENC)
Notable institutional backers of Fennec Pharmaceuticals Inc. include Rosalind Advisors, Inc., Southpoint Capital Advisors Lp, Solas Capital Management, LLC, according to Nexqual as of July 25, 2026 at 06:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rosalind Advisors, Inc. | 8.3% |
| Southpoint Capital Advisors Lp | 7.83% |
| Solas Capital Management, LLC | 7.09% |
| AIGH Capital Management LLC | 5.66% |
| AWM Investment Company, Inc. | 2.06% |
| Fidelity | 0.82% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.65% |
| Vanguard Group | 5.38% |
| Geode Capital | 1.06% |
| State Street | 1.02% |
Source: Nexqual, July 25, 2026 at 06:10 UTC.
From Fennec Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- If a third party claims that we infringe on their products or technology, we could face a number of issues, including: Third parties may assert that we are employing their proprietary technology without authorization.
- We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information.
- The laws of some foreign countries do not protect our proprietary rights to the same extent or in the same manner as United States laws, and we may encounter significant problems in protecting and defending our proprietary rights in these countries.
- We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and product are covered by valid and enforceable patents or are effectively maintained as trade secrets.
Partnerships
- On March 16, 2026, Fennec announced that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla's application to FDA for approval to market a generic version of Fennec's PEDMARK® (sodium thiosulfate injection) product.  See Fennec Pharmaceuticals Inc. v.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc. | USD 42.59 | ▼ 2.27% |
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.02 | ▼ 11.93% |
| CSBR | Champions Oncology, Inc. | USD 6.13 | ▲ 0% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
| MGTX | MeiraGTx Holdings plc | USD 11.77 | ▼ 3.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:10 UTC. This page is informational and not investment advice.